AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts
Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso (lung cancer), Lynparza (ovarian cancer), Farxiga (diabetes), and Symbicort (asthma)marketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030